Shp2 and cdk4/6 dual-target inhibitory compound and pharmaceutical composition containing the same

A compound as shown in General Formula III, and pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates, polymorphs, or prodrugs thereof

• wherein,
• ring A is selected from hydrogen,
• ring B is selected from aromatic ring, heteroaromatic ring, carbocyclic ring, heterocyclic ring;
• wherein the aromatic ring, the heteroaromatic ring, the carbocyclic ring, the heterocyclic ring optionally contain heteroatoms selected from N, O and S(O)m;
• where m is selected from 0, 1 and 2;
• where the aromatic ring, the heteroaromatic ring, the carbocyclic ring, the heterocyclic ring are optionally substituted with one or a plurality of substituents;
• L2 is a chemical bond, NRa, a carbon chain with C1-C2, O, S(O)m, where m is selected from 0, 1 and 2;
• R1, R2 are hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxyl, sulfonic acid group and C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, C6-C10 heteroaryl, respectively;
• wherein the amino, the hydroxy, the aryl, the heteroaryl, the cycloalkyl are optionally substituted with one or a plurality of substituents;
• alternatively, a 3 membered to 12 membered mono-heterocyclic ring or polycyclic heterocyclic ring is formed by R1 and R2 together with the carbon atoms attached to both R1 and R2, wherein the mono-heterocyclic ring or the polycyclic heterocyclic ring optionally contains heteroatoms selected from N, O and S(O)m;
• wherein m is selected from 0, 1 and 2;
• where the mono-heterocyclic ring or the polycyclic heterocyclic ring is unsubstituted or substituted with one or a plurality of substituents;
• alternatively,
• is formed by R1 and R2 together with the carbon atoms attached to both R1 and R2,
• wherein W is absent or selected from CR6R7, O, NRb, S(O)m, where m is selected from 0, 1 and 2;
• ring C is absent or selected from C3-C7 membered monocyclic ring, or C5-C12 membered polycyclic ring;
• Ra, Rb are independently selected from hydrogen, deuterium atoms, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, C6-C10 heteroaryl;
• R4, R5, R6, R7 are independently selected from hydrogen, deuterium atom, halogen, amino, hydroxy, cyano, nitro, carboxyl, sulfonic acid group, C1-C6 alkyl, C3-C6 cycloalkyl, C6-C10 aryl, C6-C10 heteroaryl;
• where the amino, the hydroxy, the aryl, the heteroaryl, the cycloalkyl are optionally substituted with one or a plurality of substituents;
• alternatively, CO, C═NH, C3-C12 membered heterocyclic ring or C3-C8 cycloalkyl is formed by R4 and R5 together with the carbon atoms attached to both R4 and R5.